XRTX XORTX Therapeutics Inc.
Listings ·
The consulting agreement covers up to 10 news releases over 3 months starting 9/3/2026. The fee is non-refundable, and the agreement says the services are promotional.
XORTX ended June 30, 2026 with $994,045 in cash after a $5,000,000 public offering, and the going-concern note stays. Operations used $3,768,993 in the six months.
The audit report says XORTX must finance its research or postpone it. The statements show an accumulated deficit of $23,824,557 at December 31, 2025.
The company says it needs more time for financial reporting, closing procedures and other disclosure items.
XORTX Therapeutics Inc. was incorporated in British Columbia as APAC Resources Inc. and became XORTX Therapeutics through a reverse take-over of XORTX Pharma Corp. on January 10, 2018. XORTX Pharma remains its only subsidiary. Its earlier programs centred on XORLO, a proprietary oral formulation of oxypurinol, for autosomal dominant polycystic kidney disease (ADPKD). The three-year history in the filing describes a bridging pharmacokinetics trial of XORLO, an FDA orphan drug designation for oxypurinol in ADPKD, and an orphan drug designation request for the XRx-008 program. In February 2026 the company agreed to extend the time to complete its Vectus Acquisition, which the filing says was needed to transfer intellectual property. The risk factors describe an acquisition of Psyga Bio as a transformative change to the business, with product candidates that are psychedelic and nature-derived compounds in early stages of development and not approved by any regulatory authority. The company also says it is negotiating a significant financing that would require changes to its board of directors. The filing lists operations in Calgary, Alberta and a registered office in Vancouver, British Columbia.
| Product or program | What it is | Stage |
|---|---|---|
| XORLO (oxypurinol formulation) | Proprietary oral oxypurinol formulation for ADPKD | orphan drug designation granted for oxypurinol in ADPKD |
| XRx-008 program | Program for autosomal dominant polycystic kidney disease | orphan drug designation request submitted |
| Psyga Bio product candidates | Psychedelic and nature-derived compounds acquired through Psyga Bio | early stages of development; not approved by any regulatory authority |
| Line | FY2021 | FY2020 |
|---|---|---|
| Research and development | C$853,124 | C$277,455 |
| Net income (loss) | -C$1.7 million | -C$1.3 million |
| Cash from operations | -C$6.1 million | -C$728,401 |
| Cash and equivalents | C$18.9 million | C$171,271 |
Our latest story on this, dated Aug 17, 2026: "XORTX reports $994,045 in cash and a going-concern note for first half of 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Aug 17, 2026: "XORTX reports $994,045 in cash and a going-concern note for first half of 2026". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated May 1, 2025: "XORTX Therapeutics files late-filing notice for 2024 annual report". The story links the filing or release it is based on. Read the story.
XORTX Therapeutics Inc. trades under the ticker XRTX on NASDAQ.
XORTX Therapeutics Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:A427MJ; LS:A427MJ; LSX:A427MJ.
The SEC Central Index Key (CIK) for XORTX Therapeutics Inc. is 1729214. Its filings are on SEC EDGAR.
12,989,678 shares as of 2021-12-31, per the cover page of its 20-F filed 2022-05-03.
Our directory records XORTX Therapeutics Inc. under Canada.
Our directory classifies XORTX Therapeutics Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for XORTX Therapeutics Inc. is CA98420Q4051.
aibio.space lists XORTX Therapeutics Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as A1.
XORTX Therapeutics Inc. was incorporated in British Columbia as APAC Resources Inc. and became XORTX Therapeutics through a reverse take-over of XORTX Pharma Corp. on January 10, 2018. XORTX Pharma remains its only subsidiary.
XORLO (oxypurinol formulation): Proprietary oral oxypurinol formulation for ADPKD Stage: orphan drug designation granted for oxypurinol in ADPKD.
XRx-008 program: Program for autosomal dominant polycystic kidney disease Stage: orphan drug designation request submitted.
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported a reverse stock split. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Filed a registration statement for a share offering. SEC Form F-1. Source
Reported a financing. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 20-F. Source
Told the SEC a periodic report would be filed late. SEC Form NT 20-F. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 6-K. Source
Reported a financing. SEC Form 6-K. Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio